Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

How Compass is developedGive feedback

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026

Original source

Tiziana Life Sciences to present Phase 2a BANYAN trial data at ALS Nexus 2026Proactiveinvestors NA · 24 August 2026 (opens in a new tab)

Compass holds only the headline and link for this source, so the summary below is necessarily brief. Please read the original.

Tiziana Life Sciences plans to present data from its Phase 2a BANYAN trial at ALS Nexus 2026. The trial is related to amyotrophic lateral sclerosis (ALS).

Why this matters

The presentation may provide information about the BANYAN trial to people affected by ALS, clinicians and researchers. A presentation does not by itself show that a treatment is effective or safe, and no results are available here.

Limitations and context

This is a news report about a planned presentation, not a report of trial results. The available source details do not establish the study’s findings, participant numbers, treatment effects or whether the data have been peer reviewed.

Summarised by Compass 24 August 2026

This summary was generated by AI from the source listed above. It is not medical advice, so read the original source for anything that affects your care.

Relevant to you?